Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: A meta-analysis

Diabetic Medicine

Volumn 21, Issue 2, 2004, Pages 114-121

  Ziegler, D ^a   Nowak, H ^b   Kempler, P ^c   Vargha, P ^c   Low, P A ^d  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Viatris Inc   (Germany)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d MAYO CLINIC   (United States)

Author keywords

lipoic acid; Diabetic polyneuropathy; Meta analysis; Neuropathy Impairment Score; Total Symptom Score

Indexed keywords

ANTIOXIDANT; PLACEBO; THIOCTIC ACID; TROMETAMOL;

ACHILLES REFLEX; ANALGESIA; ARTICLE; BURNING SENSATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; DATA BASE; DIABETIC NEUROPATHY; GERMANY; HEADACHE; HUMAN; META ANALYSIS; NAUSEA; PARESTHESIA; PRESSURE SENSE; RANDOMIZATION; SCORING SYSTEM; SIDE EFFECT; TOUCH; TREATMENT OUTCOME;

ANTIOXIDANTS; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; THIOCTIC ACID; TREATMENT OUTCOME;

EID: 1242337352     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01109.x     Document Type: Article

References (33)

1. Shaw JE, Zimmet PZ. The epidemiology of diabetic neuropathy. Diabetes Rev 1999; 7: 245-252.
2. Resnick HE, Vinik AI, Schwartz AV, Leveille SG, Brancati FL, Balfour J et al. Independent effects of peripheral nerve dysfunction on lower-extremity physical function in old age. The Women's Health and Aging Study. Diabetes Care 2000; 23: 1642-1647.
3. Galer BS, Gianas A, Jensen MP. Painful diabetic neuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000; 47: 123-128.
4. Forsblom CM, Sane T, Groop PH, Totterman KJ, Kallio M, Saloranta C et al. Risk factors for mortality in Type II (non-insulin-dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4. Diabetologia 1998; 4: 1253-1262.
5. Coppini DV, Bowtell PA, Weng C, Young PJ, Sönksen PH. Showing neuropathy is related to increased mortality in diabetic patients - a survival analysis using an accelerated failure time model. J Clin Epidemiol 2000; 53: 519-523.
6. Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJM. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 1998; 21: 1071-1075.
7. Ziegler D. Glycaemic control. In Gries FA, Cameron NE, Low PA, Ziegler D eds. Textbook of Diabetic Neuropathy. Stuttgart, New York: Thieme, 2003; 157-160.
8. Ziegler D, Luft D. Clinical trials for drugs against diabetic neuropathy. Can we combine scientific needs with clinical practicalities? In Tomlinson DR ed. Neurobiology of Diabetic Neuropathy. San Diego, CA: Elsevier Science, Academic Press, 2002; 431-463.
9. Low PA, Nickander KK, Tritschler HJ. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 1997; 46: S38-S42.
10. Cameron NE, Eaton SE, Cotter MA, Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001; 44: 1973-1988.
11. Nagamatsu M, Nickander KK, Schmelzer JD, Raya A, Wittrock DA, Tritschler HT et al. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995; 18: 1160-1167.
12. Cameron NE, Cotter MA, Horrobin DH, Tritschler HJ. Effects of α-lipoic acid on neurovascular function in diabetic rats: interaction with essential fatty acids. Diabetologia 1998; 41: 390-399.
13. Bock E, Schneeweiss J. Ein Beitrag zur Therapie der Neuropathia diabetica. Münchner Med Wochenschrift 1959; 43: 1911-1912.
14. Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schütte K et al. the ALADIN Study Group. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant α-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995; 38: 1425-1433.
15. Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schütte K et al. and the ALADIN III Study Group. Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid. A 7-month multicenter randomized controlled trial (ALADIN III Study). Diabetes Care 1999; 22: 1296-1301.
16. Ametov A, Barinov A, O'Brien P, Dyck PJ, Herman R, Litchy WJ et al., the SYDNEY Trial Study Group. The sensory symptoms of diabetic polyneuropathy are improved with α-lipoic acid: The SYDNEY Trial. Diabetes Care 2003; 26: 770-776.
17. NATHAN II Study. VIATRIS GmbH, data on file.
18. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999; 354: 1896-900.
19. Dyck PJ, Davies JL, Litchy WJ, O'Brien PC. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 1997; 49: 229-239.
20. Dyck PJ, Sherman WR, Hallcher LM, Service FJ, O'Brien PC, Grina LA et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 1980; 8: 590-596.
21. Young MJ, Boulton AJM, Macleod AF, Williams DRR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 150-154.
22. Egger M, Davey Smith G. Meta-analysis. Bias in location and selection of studies. Br Med J 1998; 316: 61-66.
23. Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. Br Med J 1997; 315: 640-645.
24. Davey Smith G, Egger M. Meta-analysis. Unresolved issues and future developments. Br Med J 1998; 316: 221-225.
25. Nickander KK, McPhee BR, Low PA, Tritschler H. Alpha-lipoic acid: antioxidant potency against lipid peroxidation of neural tissues in vitro and implications for diabetic neuropathy. Free Rad Biol Med 1996; 21: 631-639.
26. Mitsui Y, Schmelzer JD, Zollman PJ, Mitsui M, Tritschler HJ, Low PA. Alpha-lipoic acid provides neuroprotection from ischemia-reperfusion injury of peripheral nerve. J Neurol Sci 1999; 163: 11-16.
27. Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Lund DD, Yorek MA. Effect of antioxidant treatment of streptozotocin-induced diabetic rats on endoneural blood flow, motor nerve conduction velocity, and vascular reactivity of epineural arterioles of the sciatic nerve. Diabetes 2001; 50: 1927-1937.
28. Borcea V, Nourooz-Zadeh J, Wolff SP, Klevesath M, Hofmann M, Ulrich H et al. α-Lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria. Free Rad Biol Med 1999; 22: 1495-1500.
29. Androne L, Gavan NA, Veresiu IA, Orasan R. In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy. In Vivo 2000; 14: 327-330.
30. Haak E, Usadel KH, Kusterer K, Amini P, Frommeyer R, Tritschler HJ et al. Effects of alpha-lipoic acid on microcirculation in patients with peripheral diabetic neuropathy. Exp Clin Endocrinol Diabetes 2000; 108: 168-174.
31. Haak ES, Usadel KH, Kohleisen M, Yilmaz A, Kusterer K, Haak T. The effect of alpha-lipoic acid on the neurovascular reflex arc in patients with diabetic neuropathy assessed by capillary microscopy. Microvasc Res 1999; 58: 28-34.
32. Heitzer T, Finckh B, Albers S, Krohn K, Kohlschütter A, Meinertz T. Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med 2001; 31: 53-61.
33. Ziegler D, Reljanovic M, Mehnert H, Gries FA. α-Lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes 1999; 107: 421-430.